103 related articles for article (PubMed ID: 30025900)
1. Recent advances in peptidomimetics antagonists targeting estrogen receptor α-coactivator interaction in cancer therapy.
Qin W; Xie M; Qin X; Fang Q; Yin F; Li Z
Bioorg Med Chem Lett; 2018 Sep; 28(17):2827-2836. PubMed ID: 30025900
[TBL] [Abstract][Full Text] [Related]
2. In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α.
Singh K; Munuganti RS; Leblanc E; Lin YL; Leung E; Lallous N; Butler M; Cherkasov A; Rennie PS
Breast Cancer Res; 2015 Feb; 17(1):27. PubMed ID: 25848700
[TBL] [Abstract][Full Text] [Related]
3. Human estrogen receptor α antagonists, part 2: Synthesis driven by rational design, in vitro antiproliferative, and in vivo anticancer evaluation of innovative coumarin-related antiestrogens as breast cancer suppressants.
Kurtanović N; Tomašević N; Matić S; Mitrović MM; Kostić DA; Sabatino M; Antonini L; Ragno R; Mladenović M
Eur J Med Chem; 2022 Jan; 227():113869. PubMed ID: 34710747
[TBL] [Abstract][Full Text] [Related]
4. Estrogen Receptor α (ERα)-targeting Compounds and Derivatives: Recent Advances in Structural Modification and Bioactivity.
Guo WY; Zeng SM; Deora GS; Li QS; Ruan BF
Curr Top Med Chem; 2019; 19(15):1318-1337. PubMed ID: 31215379
[TBL] [Abstract][Full Text] [Related]
5. Designer interface peptide grafts target estrogen receptor alpha dimerization.
Chakraborty S; Asare BK; Biswas PK; Rajnarayanan RV
Biochem Biophys Res Commun; 2016 Sep; 478(1):116-122. PubMed ID: 27462021
[TBL] [Abstract][Full Text] [Related]
6. The Quest for Orally Available Selective Estrogen Receptor Degraders (SERDs).
Wang L; Sharma A
ChemMedChem; 2020 Nov; 15(22):2072-2097. PubMed ID: 32916035
[TBL] [Abstract][Full Text] [Related]
7. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor alpha mediates progestin-induced mammary tumor growth by interacting with progesterone receptors at the cyclin D1/MYC promoters.
Giulianelli S; Vaqué JP; Soldati R; Wargon V; Vanzulli SI; Martins R; Zeitlin E; Molinolo AA; Helguero LA; Lamb CA; Gutkind JS; Lanari C
Cancer Res; 2012 May; 72(9):2416-27. PubMed ID: 22396492
[TBL] [Abstract][Full Text] [Related]
9.
Bouricha EM; Hakmi M; Akachar J; Zouaidia F; Ibrahimi A
J Biomol Struct Dyn; 2022 Jul; 40(11):5203-5210. PubMed ID: 33402049
[TBL] [Abstract][Full Text] [Related]
10. Design and Synthesis of Novel Breast Cancer Therapeutic Drug Candidates Based upon the Hydrophobic Feedback Approach of Antiestrogens.
Ohta K; Kaise A; Taguchi F; Aoto S; Ogawa T; Endo Y
Molecules; 2019 Nov; 24(21):. PubMed ID: 31683895
[TBL] [Abstract][Full Text] [Related]
11. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
12. In silico identification of novel inhibitors targeting the DNA-binding domain of the human estrogen receptor alpha.
Cao H; Sun Y; Wang L; Pan Y; Li Z; Liang Y
J Steroid Biochem Mol Biol; 2021 Oct; 213():105966. PubMed ID: 34416373
[TBL] [Abstract][Full Text] [Related]
13. Modulation of estrogen receptor alpha protein level and survival function by DBC-1.
Trauernicht AM; Kim SJ; Kim NH; Boyer TG
Mol Endocrinol; 2007 Jul; 21(7):1526-36. PubMed ID: 17473282
[TBL] [Abstract][Full Text] [Related]
14. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
[TBL] [Abstract][Full Text] [Related]
15. Dynamics-Based Discovery of Novel, Potent Benzoic Acid Derivatives as Orally Bioavailable Selective Estrogen Receptor Degraders for ERα+ Breast Cancer.
Zhang X; Wang Y; Li X; Wu J; Zhao L; Li W; Liu J
J Med Chem; 2021 Jun; 64(11):7575-7595. PubMed ID: 34056898
[TBL] [Abstract][Full Text] [Related]
16. Development of cell-permeable peptide-based PROTACs targeting estrogen receptor α.
Dai Y; Yue N; Gong J; Liu C; Li Q; Zhou J; Huang W; Qian H
Eur J Med Chem; 2020 Feb; 187():111967. PubMed ID: 31865016
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor α roles in breast cancer chemoresistance.
Xu CY; Jiang ZN; Zhou Y; Li JJ; Huang LM
Asian Pac J Cancer Prev; 2013; 14(7):4049-52. PubMed ID: 23991950
[TBL] [Abstract][Full Text] [Related]
18. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
[TBL] [Abstract][Full Text] [Related]
19. Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer.
Burks HE; Abrams T; Kirby CA; Baird J; Fekete A; Hamann LG; Kim S; Lombardo F; Loo A; Lubicka D; Macchi K; McDonnell DP; Mishina Y; Norris JD; Nunez J; Saran C; Sun Y; Thomsen NM; Wang C; Wang J; Peukert S
J Med Chem; 2017 Apr; 60(7):2790-2818. PubMed ID: 28296398
[TBL] [Abstract][Full Text] [Related]
20. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
